Genflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development

Reuters2025-09-30

Genflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development

**Genflow Biosciences plc Advances SIRT6 Platform with New Regional Grant** London, September 30, 2025 - Genflow Biosciences plc (LSE:GENF, OTCQB:GENFF) announced in its latest half-year report that the company has received support from the Wallonia Region to advance its proprietary gene therapy candidate, GF-1002, through the next stage of development. The grant, which is currently in the finalization process, will provide non-dilutive funding to accelerate progress toward clinical readiness. Genflow did not specify whether the grant was awarded to multiple organizations or solely to Genflow Biosciences. The company anticipates sharing further updates once the grant process is complete and payment is received. This funding is expected to support Genflow's ongoing efforts in developing therapies targeting age-related diseases and enhancing healthspan in both human and veterinary applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1079834) on September 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2571189513?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571189513","market":"fut","top_or_hot":-1,"title":"Genflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Genflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Genflow Biosciences plc Advances SIRT6 Platform with New Regional Grant** London, September 30, 2025 - Genflow Biosciences plc (LSE:GENF, OTCQB:GENFF) announced in its latest half-year report that the company has received support from the Wallonia Region to advance its proprietary gene therapy candidate, GF-1002, through the next stage of development. The grant, which is currently in the finalization process, will provide non-dilutive funding to accelerate progress toward clinical readiness. Genflow did not specify whether the grant was awarded to multiple organizations or solely to Genflow Biosciences. The company anticipates sharing further updates once the grant process is complete and payment is received. This funding is expected to support Genflow's ongoing efforts in developing therapies targeting age-related diseases and enhancing healthspan in both human and veterinary applications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1079834) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Genflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Genflow Biosciences plc Advances SIRT6 Platform with New Regional Grant** London, September 30, 2025 - Genflow Biosciences plc (LSE:GENF, OTCQB:GENFF) announced in its latest half-year report that the company has received support from the Wallonia Region to advance its proprietary gene therapy candidate, GF-1002, through the next stage of development. The grant, which is currently in the finalization process, will provide non-dilutive funding to accelerate progress toward clinical readiness. Genflow did not specify whether the grant was awarded to multiple organizations or solely to Genflow Biosciences. The company anticipates sharing further updates once the grant process is complete and payment is received. This funding is expected to support Genflow's ongoing efforts in developing therapies targeting age-related diseases and enhancing healthspan in both human and veterinary applications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1079834) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GENF.UK","symbol_name":"GENFLOW BIOSCIENCES PLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDLc3Cvky:1","article_id":"2571189513","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571189513","pubTimestamp":1759212036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Genflow Biosciences plc Advances SIRT6 Platform with New Regional Grant** London, September 30, 2025 - Genflow Biosciences plc  announced in its latest half-year report that the company has received support from the Wallonia Region to advance its proprietary gene therapy candidate, GF-1002, through the next stage of development. The grant, which is currently in the finalization process, will provide non-dilutive funding to accelerate progress toward clinical readiness. Genflow did not specify whether the grant was awarded to multiple organizations or solely to Genflow Biosciences. The company anticipates sharing further updates once the grant process is complete and payment is received. This funding is expected to support Genflow's ongoing efforts in developing therapies targeting age-related diseases and enhancing healthspan in both human and veterinary applications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GENF.UK":"GENFLOW BIOSCIENCES PLC","BK5083":"生物科技"},"translate_title":"Genflow Biosciences获得瓦隆地区拨款，以推进SIRT6基因治疗项目GF-1002的临床开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GENF.UK":0.9},"content_text":"Genflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development\n    \n\n        **Genflow Biosciences plc Advances SIRT6 Platform with New Regional Grant** London, September 30, 2025 - Genflow Biosciences plc (LSE:GENF, OTCQB:GENFF) announced in its latest half-year report that the company has received support from the Wallonia Region to advance its proprietary gene therapy candidate, GF-1002, through the next stage of development. The grant, which is currently in the finalization process, will provide non-dilutive funding to accelerate progress toward clinical readiness. Genflow did not specify whether the grant was awarded to multiple organizations or solely to Genflow Biosciences. The company anticipates sharing further updates once the grant process is complete and payment is received. This funding is expected to support Genflow's ongoing efforts in developing therapies targeting age-related diseases and enhancing healthspan in both human and veterinary applications.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1079834) on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2571189513","isCrawlerRequest":true}